uniQure surges following departure of key FDA official
Source: SeekingAlpha
2026-03-09 09:01:47 ET
More on uniQure
- uniQure: Worst Case Scenario Becomes Reality
- uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade)
- uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
- uniQure used 'distorted comparison' in Huntington's asset trial: FDA official
- uniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130
Read the full article on Seeking Alpha
For further details see:
uniQure surges following departure of key FDA official
uniQure N.V.
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
